At a glance
ClinicalIndex Comparison RecordPhase 2Active· 52 enrolled
Drug / intervention
Simvastatin +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Statin Therapy to Reduce Disease Progression From Liver Cirrhosis to Cancer
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Computed Tomography, and 4 other interventions for Cirrhosis and Hepatocellular Carcinoma. Active but no longer recruiting, targeting 52 participants across 5 sites in 2 countries.
Detailed Summary
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis, Hepatocellular Carcinoma
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2Active
20172018201920202021202220232024202520262027
First PostedNov 2016
Enrollment StartJun 2017
Primary CompletionMay 2023
TodayJul 2026
Study CompletionDec 2026
First PostedNov 21, 2016
Enrollment StartJun 21, 2017
Primary CompletionMay 3, 2023
Study CompletionDec 23, 2026
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 9.6 years ago
Interventions
Biospecimen Collectionprocedure
Undergo collection of blood
Computed Tomographyprocedure
Undergo CT
Magnetic Resonance Imagingprocedure
Undergo MRI
Placebo Administrationother
Given PO
Questionnaire Administrationother
Ancillary studies
Simvastatindrug
Given PO